HLS Therapeutics (TSE:HLS) Price Target Raised to C$5.00 at Raymond James

HLS Therapeutics (TSE:HLS) had its price objective hoisted by Raymond James from C$4.00 to C$5.00 in a report released on Friday morning,BayStreet.CA reports.

Separately, Stifel Nicolaus reduced their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.

HLS Therapeutics Stock Performance

HLS stock opened at C$3.50 on Friday. The company has a market capitalization of C$111.27 million, a P/E ratio of -3.47 and a beta of 1.07. The company has a 50-day simple moving average of C$3.54 and a 200 day simple moving average of C$3.48. HLS Therapeutics has a fifty-two week low of C$3.00 and a fifty-two week high of C$5.48. The company has a quick ratio of 1.01, a current ratio of 2.02 and a debt-to-equity ratio of 100.44.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.